Dr. David James Pinato

New cancer therapies

Clinical Senior Lecturer and Consultant Medical Oncologist

(MD MRCP (UK) MRes PhD)


Joined in 2019.

Dr Pinato leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. He has led the inception of a portfolio of first-in-class studies of immune checkpoint inhibitors in liver cancer, which has represented Dr Pinato’s focus of research since graduation with the highest honours at the University of Piemonte Orientale “A. Avogadro” in Novara, Italy.

He also completed his core medical training across some of the busiest acute hospitals in London, being elected member of the Royal College of Physicians (MRCP) in 2014. He has trained in Medical Oncology as part of the Royal Marsden Hospital rotation, having migrated to Imperial College in April 2015 to take up a Clinical Lectureship funded by the National Institute for Health Research (NIHR).

In 2018 Dr Pinato was awarded a Clinician Scientist fellowship funded by the Wellcome Trust Strategic Fund centred on the development of immunotherapy in liver cancer. Additionally, Dr Pinato’s research efforts on biomarker discovery have been recognized with the prestigious Merit Award from the American Society of Clinical Oncology (ASCO) three times in 2016, 2017, 2019 as well as a fourth Merit Award jointly awarded by ASCO and by the Society for Immunotherapy of Cancer (SITC) in 2019. In 2019 Dr Pinato was awarded the prestigious ASCO Global Oncology Young Investigator Award in recognition of his research on HIV-associated hepatocellular cancer. He was also awarded a prize by the British Society of Pharmacology in 2018 and the Sylvia Lawler Prize in Oncology from the Royal Society of Medicine in 2016.

Dr Pinato lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for a number of peer-reviewed journals including Hepatology, Journal of Hepatology, Oncogene, OncoImmunology, Gut and many others. He has acted as a peer reviewer for a number of grant-awarding bodies including the MRC, Breast Cancer Now and Cancer Research UK.

Return to our trustees